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ANALYSIS OF FACTORS THAT INFLUENCE SHORT-
TERM INCREASE IN BMI AMONG CHILDREN RECENTLY 
DIAGNOSED WITH DIABETES 
 
            Abidemi K. Adeniji, M.S. 
        University of Pittsburgh, 2008 
 
There is extensive literature on the etiology of Type 1 diabetes mellitus (T1DM). T1DM 
is a disease that has levied a substantial burden on the health of millions; as such a study into the 
factors associated with T1DM is of utmost importance in the field of public health.  It is widely 
believed that a person’s genetic predisposition is linked with the susceptibility of T1DM.  Some 
genes are largely unknown, while some like the HLA gene class II molecules DQ has been 
greatly studied. It is believed that the haplotype Non-Asp/0602 is actually protective against 
T1DM.  The risk of Type 1 diabetes in individuals with a genetic susceptibility- homozygous 
non-Asp/non-Asp are at higher risk whereas the individuals with Asp/Asp are at lower risk of 
Type 1 diabetes.  Studies have suggested that those patients who are at greatest risk genetically 
tend to have a low body mass index (BMI), low pro-insulin, and a higher number of positive 
antibodies. In the past, children diagnosed with type 1 diabetes were not overweight and actually 
would present with considerable weight loss and underweight. This seems to be changing.  
The purpose of this study is to investigate precipitating factors that are associated with 
short-term weight gain in children who were diagnosed with T1DM at Children’s Hospital of 
Pittsburgh, from 2004 through 2006. We investigated the prevalence of increased BMI after 3 
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months of diagnosis in patients with Type 1 diabetes in relation to BMI at onset, gender, age at 
onset, HLA-DQ type, C-peptide, hemoglobin A1c (HbA1c) and race. 
BMI percentile at diagnosis was significantly different from BMI percentile at 3months, 
which showed an average increase from baseline of 21.5 and a standard deviation of 24.6 (p-
value<0.0001, paired t-test).  Greater change in BMI percentile from onset to 3 months was 
significantly associated with younger age, higher HbA1c, male gender and being under the 25th 
percentile in BMI at onset.  The subjects with the highest BMI percentile at 3 months were 
significantly associated with the independent predictors of younger age, higher HbA1c, male 
gender and being in the 85th percentile in BMI at onset.  
 
 
 
 
 
 v 
TABLE OF CONTENTS 
ACKNOWLEDGEMENTS ....................................................................................................... XI 
1.0  INTRODUCTION ........................................................................................................ 1 
1.1  PURPOSE OF THE STUDY .............................................................................. 1 
1.2  BACKGROUND AND SIGNIFICANCE .......................................................... 3 
1.3  THE PATHOLOGY OF IDDM ......................................................................... 4 
1.3.1  HLA & DQ..................................................................................................... 6 
2.0  MATERIALS AND METHODS ................................................................................ 8 
2.1  THE STUDY POPULATION ............................................................................. 8 
2.2  MEASUREMENTS AND HLA-DQ TYPING .................................................. 8 
2.3  BLOOD PRESSURE PERCENTILES .............................................................. 9 
2.4  BP TABLES ....................................................................................................... 10 
2.4.1  Blood Pressure Percentile Computation ................................................... 10 
2.5  WAIST CIRCUMFERENCE ........................................................................... 11 
2.5.1  Waist Circumference Percentiles .............................................................. 11 
2.6  CONSOLIDATING DATA ............................................................................... 12 
2.6.1  Waist and HIP ............................................................................................. 12 
2.6.2  Antibody GAD ............................................................................................. 13 
2.6.3  Antibody IA2 ............................................................................................... 13 
 vi 
2.6.4  Lipids ............................................................................................................ 13 
2.6.5  C-peptide ...................................................................................................... 13 
2.6.6  Baseline Height ............................................................................................ 14 
2.7  THE CREATION OF INDICATOR VARIABLES ....................................... 14 
2.7.1  Waist class.................................................................................................... 14 
2.7.2  BMI class...................................................................................................... 15 
2.7.3  Antibodies .................................................................................................... 15 
2.8  STATISTICAL METHODS ............................................................................. 16 
3.0  RESULTS ................................................................................................................... 17 
3.1.1  Demographics .............................................................................................. 17 
3.1.2  Distribution Continuous Predictors .......................................................... 18 
3.1.3  Distribution Categorical Predictors .......................................................... 20 
3.1.4  Interpretation of the Regression Models .................................................. 23 
4.0  DISCUSSION ............................................................................................................. 27 
5.0  CONCLUSION ........................................................................................................... 28 
APPENDIX: TABLES ................................................................................................................ 29 
BIBLIOGRAPHY ....................................................................................................................... 34 
 vii 
 LIST OF TABLES 
 
TABLE 1. CROSS TABULATION DEPICTING THE RELATIONSHIP BETWEEN 
GENDER AND RACE AMONG STUDY PARTICIPANTS. ................................................ 17 
TABLE 2.  DESCRIPTIVE STATISTICS FOR BASELINE VARIABLES USED IN THE 
STUDY OF TYPE I DIABETES IN CHILDREN. .................................................................. 18 
TABLE 3.  DESCRIPTIVE STATISTICS FOR VARIABLES AT TIME 3-MONTHS 
USED IN THE STUDY OF TYPE I DIABETES IN CHILDREN. ....................................... 19 
TABLE 4.  DESCRIPTIVE STATISTICS FOR AVERAGE THREE MONTH CHANGE.
....................................................................................................................................................... 20 
TABLE 5.  FREQUENCY DISTRIBUTION OF HLA/DQ, WAIST PERCENTILES, 
WAIST CLASS AND BMI CLASS. .......................................................................................... 21 
TABLE 6.  REGRESSION COEFFICIENTS FOR BMI CHANGE AS OUTCOME. ....... 24 
TABLE 7.  REGRESSION COEFFICIENTS FOR BMI AT 3-MONTHS AS OUTCOME.
....................................................................................................................................................... 25 
TABLE 8.  CROSS TABULATION DEPICTING THE RELATIONSHIP BETWEEN 
POSITIVE ANTIBODIES AND HLA. ..................................................................................... 26 
TABLE 9.  CROSS TABULATION DEPICTING THE RELATIONSHIP BETWEEN 
HLA AND BMI. .......................................................................................................................... 26 
 viii 
TABLE 1A. REGRESSION COEFFICIENTS FROM STUDY OF BLOOD PRESSURE. 29 
TABLE 1B. WAIST PERCENTILES FOR EUROPEAN AMERICAN BOYS ................... 30 
TABLE 1C.  WAIST PERCENTILES EUROPEAN AMERICAN GIRLS ......................... 31 
TABLE 1D.  WAIST PERCENTILES AFRICAN AMERICAN BOYS ............................... 32 
TABLE 1E.  WAIST PERCENTILES AFRICAN AMERICAN GIRLS ............................. 33 
 
 
 
 
 
 
 
 
 ix 
 LIST OF FIGURES 
FIGURE 1: PERCENT DISTRIBUTION OF HLA/DQ ......................................................... 22 
FIGURE 2: PERCENT DISTRIBUTION OF WAIST CLASS ............................................. 22 
FIGURE 3: PERCENT DISTRIBUTION OF BMI CLASS................................................... 23 
 
 x 
ACKNOWLEDGEMENTS 
I would like to express my sincere gratitude to my thesis advisor, Dr. Vincent Arena.  
Thank you so much for giving me the opportunity to work with and learn from you.  I appreciate 
all of the time and resources you extended to me along the way. The experience has been 
invaluable. 
I would like to thank Dr. Ingrid Libman for taking the time to clarify the genetic aspects 
of the study, the genetic theory behind Type 1 diabetes and for your encouragement and 
suggestions.  
Much thanks to Ms. Maribel Cedillo for her assistance in navigating through the grant 
proposal, as well as the specific aims of the project.  I appreciate your help in defining my study 
population. 
I would like to thank Dr. Dorothy Becker for allowing me the opportunity to work on 
such an extensive diabetes data set, and for allowing me to work with her research team.  
Working with you has increased my interest in researching diabetes.    
Much gratitude is owed to my fiancée, Stephanie Miller.  Last, but not the least, I would 
like to thank my family, friends and classmates for all of their support throughout my tenure in 
the program.  I appreciate your support and wisdom. 
 
 
 xi 
 xii 
 
1.0  INTRODUCTION 
1.1 PURPOSE OF THE STUDY 
There is extensive literature on the etiology of Type 1 diabetes mellitus (T1DM). T1DM 
is a disease that has levied a substantial burden on the health of millions; as such a study into the 
factors associated with T1DM is of utmost importance in the field of public health.  It is widely 
believed that a person’s genetic predisposition is linked with the susceptibility of T1DM.  Some 
genes are largely unknown, while some like the HLA gene class II molecules DQ has been 
greatly studied. It is believed that the haplotype Non-Asp/0602 is actually protective against 
T1DM.  The risk of Type 1 diabetes in individuals with a genetic susceptibility- homozygous 
non-Asp/non-Asp were at the highest risk whereas as the individuals with Asp/Asp were at the 
lowest risk of Type 1 diabetes [20].  Studies have suggested that those patients who are at 
greatest risk genetically tend to have a low body mass index (BMI), low pro-insulin, and a higher 
number of positive antibodies. In the past, children diagnosed with type 1 diabetes were not 
overweight and actually would present with considerable weight loss and underweight. This 
seems to be changing. In fact, it has been proposed that excessive weight gain may be a 
contributing factor to the development of type 1 diabetes [24].  
The origins of Type 1 are not fully understood. Ten percent of people diagnosed with 
diabetes have Type 1 and the majority of them are children or young adults when it strikes. 
Genetic factors are important; however scientists believe that environmental factors also play an 
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important role, among them viral infections. Several clinical trials of methods for the prevention 
of type 1 diabetes are currently in progress or are being planned. 
There are no known preventative measures that prevent Type 1 diabetes.  Most people 
affected by Type 1 diabetes are otherwise healthy and traditionally not overweight when onset 
occurs.  Diet and exercise cannot reverse or prevent Type 1 diabetes.  On the other hand, Type II 
diabetes seems to be prevented or delayed with modifications in diet and exercise. As such, I am 
interested in understanding and investigating ways to prevent obesity in children.  According to 
the CDC, the percentage of young people who are overweight has more than tripled since 1980, 
and 16% of children aged 6-19 considered overweight. This increase has also been described in 
children diagnosed with type 1 diabetes at onset of the disease [25] 
The purpose of this study is to investigate precipitating factors that are associated with 
short-term weight gain in children who were diagnosed with T1DM at Children’s Hospital of 
Pittsburgh. We investigated the prevalence of increased BMI at 3 months after diagnosis in 
patients with Type 1 diabetes in relation to BMI at onset, gender, age at onset, HLA-DQ type, C-
peptide, HbA1c and race. 
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1.2 BACKGROUND AND SIGNIFICANCE 
 
DIABETES OVERVIEW 
 
Type 1 diabetes accounts for between 5 and 10% of all diagnosed diabetes in the United 
States.  Although Type 1 diabetes develops most often in children and young adults (one in every 
400-600 children has Type 1 diabetes) [1], the disease can be diagnosed at any age throughout 
the lifespan, and is equally distributed among males and females.  Unlike Type 2 diabetes, Type 
1 diabetes is more common in Caucasians than in those of Latino, African-American, or other 
non-Caucasian backgrounds.  
Type 1 diabetes is an autoimmune disease that occurs when the insulin-producing β cells 
within the pancreas are gradually destroyed and eventually fail to produce insulin.  Insulin is a 
hormone that helps the body's cells use glucose for energy.  Blood glucose (or blood sugar) is 
manufactured from the food we eat (primarily carbohydrates) and by the liver.  If glucose cannot 
be absorbed by the cells, it builds up in the bloodstream, and eventually leads to high blood 
sugar.  Over time, the high blood glucose levels of uncontrolled diabetes can be toxic to virtually 
every system of the body.  As a result, individuals with T1D require daily exogenous insulin 
treatment as well as frequent surveillance of blood glucose levels. 
After eating, the glucose level in blood rises, which leads to insulin being released from 
the pancreas.  In a person with TIDM, beta cells of Langerhans are damaged by autoimmune 
inflammation, leading to an insufficiency of insulin.  The glucose level in blood rises and cells 
do not have enough energy for metabolism [3].  
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 1.3 THE PATHOLOGY OF IDDM 
Type 1 diabetes is a chronic autoimmune disease resulting from the progressive 
destruction of the pancreatic β-cells, which in turn leads to an absolute insulin deficiency [9].  
The timing of the clinical presentation is highly variable, with the youngest patients diagnosed in 
infancy and the oldest patients diagnosed at a senior age. It is believed that at least half of the 
inherited genetic predisposition to Type 1 diabetes is due to HLA-DQ genes [6].   
People with type 1 diabetes develop an abnormal immune reaction which causes T-cells 
to destroy the insulin producing cells in the pancreas. Antibodies are markers of this process and 
the ones that are well described include are ICA (Islet cell antibodies), the insulin auto-
antibodies (IAA), auto-antibodies to glutamic acid decarboxylase (GAD) and auto-antibodies 
against the protein tyrosine phosphatase (IA-2A). 
The clinical onset of diabetes does not occur until 80% to 90% of these cells are 
destroyed. Prior to clinical onset, Type 1 diabetes is often characterized by circulating auto-
antibodies against a variety of islet cell antigens, including glutamic acid decarboxylase (GAD), 
tyrosine phosphatase (IA2), and insulin [10-15].  The autoimmune destruction of the insulin-
producing pancreatic beta cells is thought to be the primary cause of Type 1 diabetes.  Auto-
antibodies are valuable markers that predict Type 1 diabetes and can be detected many months or 
years before the onset of diabetes [2]. The presence of these auto-antibodies provides early 
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evidence of autoimmune disease activity, and their measurement can be useful in assisting the 
physician with the prediction, and diagnosis, of patients with diabetes. 
Glutamic acid decarboxylase-65 (GAD65) is an enzyme that is produced primarily by 
pancreatic islet cells. A number of recent studies indicate that patients with insulin-dependent 
diabetes mellitus (IDDM) often have antibodies to GAD65 and several other islet cell antigens 
[7]. This is consistent with the hypothesis that IDDM is an autoimmune disease and that 
autoantibody production is an early step in the development of IDDM.  Auto-antibodies can be 
detected in many cases prior to the onset of glucose intolerance.  The presence of GAD65 auto-
antibodies is shown to be a strong predictive marker for the eventual onset of IDDM.  
Measurement of GAD65 antibody can also be of use in distinguishing insulin-dependent from 
non-insulin-dependent diabetics when the clinical history is ambiguous [8].  
Auto-antibodies to IA2 (IA2A), a tyrosine phosphatase-like protein, are found in 50% to 
75% of Type 1 diabetics at and prior to disease onset.  These auto-antibodies are generally more 
prevalent in younger onset patients. Because the risk of diabetes increases with the presence of 
each additional autoantibody, the positive predictive value of the IA2 antibody test is enhanced 
when measured in conjunction with antibodies to GAD and insulin. 
Insulin auto-antibodies (IAA) are one of several markers for Type I (autoimmune) 
diabetes, but alone deserve special attention.  Unlike the other markers, their ligand is unique to 
the beta cell.  IAA are the first markers to appear during the symptomless period which precedes 
diabetes and they are present in the vast majority of young children destined to develop diabetes.  
The primary and tertiary structures of insulin have been known for decades [16]. 
C-peptide is a substance that the pancreas releases into the bloodstream in equimolar 
concentrations with insulin.  A test of C-peptide levels will show just how much insulin the body 
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is making [23], and thus is a measure of insulin secretion.  C-peptide has proven to be invaluable 
in the study of the natural history of IDDM.   
Hemoglobin A1C (HbA1C) is a substance of red blood cells that carries oxygen to the 
cells and sometimes joins with glucose (sugar).  Because the glucose stays attached for the life of 
the cell (about 3 months), a test to measure hemoglobin A1C shows what the person's average 
blood glucose level during that time period.  In the blood, glucose binds irreversibly to 
hemoglobin molecules within red blood cells.  The amount of glucose that is bound to 
hemoglobin is directly tied to the concentration of glucose in the blood.  Since red blood cells 
have a lifespan of approximately 90 days, measuring the amount of glucose bound to 
hemoglobin can provide an assessment of average blood sugar control during the 60 to 90 days 
prior to the test.  This is the purpose of the glycated hemoglobin tests, most commonly the 
hemoglobin A1C (HbA1c) measurement.  Since the test results give feedback on the previous 
two to three months, getting an HbA1c test done every three months will give a good estimate of 
a persons’ average blood sugar [18]. 
1.3.1 HLA & DQ 
The human leukocyte antigen (HLA) complex is located on chromosome 6.  It is the 
primary region of susceptibility for Type 1 diabetes mellitus, as well as other autoimmune 
disorders.  The DQ locus consists of two tightly linked genes (DQA1 and DQB1) that encode α 
and β glycoprotein, respectively [19]. 
Past studies have confirmed that subjects presenting with Type 1 diabetes during 
childhood have a stronger HLA-defined genetic susceptibility than those diagnosed during 
adulthood [4, 5].  This indicates that highly predisposing HLA genes not only increase the risk of 
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Type 1 diabetes, but also have an effect on the rate of progression to clinical disease. The weaker 
HLA-conferred genetic risk in adults raises the issue of whether adult patients carry stronger 
disease susceptibility as defined by non-HLA genes or whether they experience more exogenous 
factors, which predisposes them to Type 1 diabetes in the preclinical period [7]. 
The risk of Type 1 diabetes in individuals with the genetic susceptibility- homozygous 
non-Asp/non-Asp is the highest, whereas the individuals with Asp/Asp have the lowest risk of 
Type 1 diabetes [20].  
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2.0  MATERIALS AND METHODS 
2.1 THE STUDY POPULATION 
The population studied consists of individuals who were newly diagnosed with IDDM at 
the Children’s Hospital of Pittsburgh.  These clinically diagnosed IDDM patients were recruited 
and termed “new onsets”.  New onsets are defined as children less than 19 years of age 
diagnosed with insulin-requiring diabetes. This study was approved by the Institutional Review 
Board (IRB) of the University of Pittsburgh and parents provided informed written consent.  The 
individuals in the study were recruited from January 2004 through December 2006.  Exclusion 
was based on the presence of any severe illness, or other abnormality that could interfere with 
the assessment of T-cell function.  
 
2.2 MEASUREMENTS AND HLA-DQ TYPING 
The children had various testing and measurements done prior to discharge from the 
hospital.  At the time of diagnosis, blood samples were obtained to determine HLA-DQ typing, 
HbA1C, lipids and C-peptide levels. Height and weight measurements were also obtained to 
calculate body mass index (BMI).  The patients first study blood draw for autoantibody (GAD65, 
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IA2) analysis was done within 3 months of diagnosis; this is done to assess their autoantibody 
status at the onset of IDDM. Antibody analysis is believed to change over time as disease 
progresses. At the time of autoantibody analysis, HbA1C, lipids, C-peptide levels, waist/hip 
measurements, blood pressure, height and weight were also ascertained. 
  
2.3 BLOOD PRESSURE PERCENTILES 
Advances have been made in detection and evaluation of high blood pressure (BP), or 
hypertension, in children and adolescents.  Because of the development of a large national 
database on normative BP levels throughout childhood, the ability to identify children who have 
abnormally elevated BP has improved.  On the basis of developing evidence, it is now apparent 
that primary hypertension is detectable in the young and occurs commonly.  The long-term 
health risks for hypertensive children and adolescents can be substantial; therefore, it is 
important that clinical measures be taken to reduce these risks and optimize health outcomes.  
Hypertension in children and adolescents continues to be defined as systolic BP (SBP) 
and/or diastolic BP (DBP), that is, greater than the 95th percentile.  BP between the 90th and 
95th percentile in childhood had been designated “high normal.”  To be consistent with the 
Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure (JNC 7), this level of BP is deemed “pre-hypertensive”.  
 It is now recommended that adults, children and adolescents who have BP levels 
≥120/80 mm Hg but <95th percentile be considered pre-hypertensive.  The definition of 
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hypertension in children and adolescents is based on the normative distribution of BP in healthy 
children.  
Normal BP is defined as SBP and DBP that are <90th percentile for gender, age, and 
height.  Hypertension is defined as average SBP or DBP that is ≥95th percentile for gender, age, 
and height on at least 3 separate occasions.  Average SBP or DBP levels that are ≥90th percentile 
but <95th percentile had been designated as “high normal” and were considered to be an 
indication of heightened risk for developing hypertension.  
2.4 BP TABLES 
The blood pressure standards are based on gender, age, and height, and it provides a 
precise classification of BP according to body size.  BP standards that are based on gender, age, 
and height provide a more precise classification of BP according to body size.  This approach 
avoids misclassifying children who are very tall or very short.   
2.4.1 Blood Pressure Percentile Computation 
To compute the SBP percentile of a boy who is age y years and height h inches with SBP 
=x mm Hg, we referred to the most recent Centers for Disease Control and Prevention growth 
charts [21], and converted the height of h inches to a height Z score relative to boys of the same 
age, this is denoted by Zht.  We then computed the expected SBP (µ) for boys of age y years and 
height h inches which given by,   
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The boy’s observed SBP is then converted to a Z score.  The formula is as follows: (Zbp) 
given by Zbp= (x-µ)/σ, where σ is given in the third column of Appendix Table 1A.  Finally, we 
converted the blood pressure Z score to a percentile (P), compute P=Φ(Zbp) *100%, where Φ(Z) 
is the area under a standard normal distribution to the left of Z. Thus, if Zbp= 1.28, then Φ(Zbp)= 
0.90 and the BP percentile= 0.90*100%= 90% [21].  Appendix Table 1A shows regression 
coefficients from blood pressure regression models. 
 
2.5  WAIST CIRCUMFERENCE 
2.5.1 Waist Circumference Percentiles 
Research has supported the notion that the trends in waist circumference in the US adult 
population and the waist circumference cutoff points which are used in identifying risk of co 
morbidity in adults, differ according to race [22].  Thus, waist percentiles based on age, gender 
and ethnicity is a critical tool in the assessment of a child’s adiposity.  Although waist-to-hip 
ratio has been widely accepted in the past, more recently, there is a consensus that waist 
circumference alone may be a more useful index in both adults and children [22].   
Due to the fact that the distribution of waist circumference according to age is not 
normally distributed, the 10th, 25th, 50th, 75th, and 90th percentiles of the waist circumference 
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distribution are examined for each race/ethnic gender classification.  After consulting with the 
author Dr. Fernandez, we obtained an additional percentile category, the 85th.  
A percentile regression approach was used to describe the changes in the percentile 
estimates as a function of age for every ethnic/gender group [22].  The following tables list the 
variables that were used in calculating the percentiles for each participant’s waist.  Appendix 
Table 1B through Table 1E gives the estimated value for percentile regression for European-
American Boys, European-American Girls, African- American Boys and African-American 
girls. 
2.6  CONSOLIDATING DATA 
2.6.1 Waist and HIP  
The date of the waist and hip measurements was matched with the three month height 
and weight date from the baseline cohort data.  This initial match produced 205 subjects, we then 
matched within a span of 14 days of the height and weight date, this produced 207 subjects.  
Further exploration was done to measure just how much more subjects could be gained by 
relaxing the window around the height and weight date.  The span was widened to a span of 120 
days; this only produced one additional subject.  The researchers agreed to consider those 
participants with a span of 14 days, which gave us a sample of 207 subjects. 
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2.6.2 Antibody GAD 
The date of the GAD65 antibody blood draw was matched with the height and weight date 
of the baseline cohort data. This produced 149 GAD65 values.   
2.6.3 Antibody IA2 
The date of the IA-2 antibody blood draw was matched with the height and weight date 
of the baseline cohort data and produced 124 IA2 values. Antibodies were analyzed for those 
subjects who had values for both antibodies (GAD65, IA2).  However, due to sparse data, 
antibodies received no further consideration in the final analyses. 
2.6.4  Lipids 
The Heinz lab blood draw date of cholesterol, triglyceride, HDL and LDL were matched 
with the height and weight date of the baseline cohort data and  229 subjects matched for lipids. 
2.6.5 C-peptide  
The blood draw date of the C-peptide values from Dr. Becker’s lab were matched with 
the height and weight date of the baseline cohort data at 3 months, this produced 228 subjects. C-
peptide values that were less than detectable were set to 0.5.  
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2.6.6 Baseline Height 
We had 268 subjects who had a BMI at baseline and at 3 months. However, height does 
not change significantly in 3 months, so we decided to use the 3 month height of subjects that 
were missing a baseline height, thereby increasing the number of subjects who had both BMI 
measurements to 295.  
2.7 THE CREATION OF INDICATOR VARIABLES 
2.7.1 Waist class 
Waist percentiles were categorized ‘0’ if the subjects waist fell under the 10th percentile, 
‘1’ if the waist fell above the 10th percentile but below the 25th percentile, ‘2’ if the waist fell 
above 25th percentile but below the 50th percentile, ‘3’ if the waist fell above the 50th percentile 
but below the 75th percentile,  ‘4’ if the waist fell above the 75th percentile but below the 85th 
percentile ‘5’ if the waist fell above the 85th percentile but below the 90th , and ‘6’ if the waist 
fell above the 90th percentile. Due to sparse data, the 7 categories stated above, were collapsed 
into two categories ‘0’ if a subject’s waist is less than the 75th percentile and ‘1’ for the 75th 
percentile and upwards. 
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2.7.2 BMI class 
Body Mass Index (BMI) is a number that reflects how a person’s weight compares to the 
person’s height, the general formula for calculating BMI is as follows: weight/height2. Weight is 
expressed in kilograms and height in centimeters. However, this form of BMI is inaccurate due 
to the difference in the growth rate between boys and girls as well as the difference in growth 
rates among ages.  Thus, BMI percentile is a better index since it adjusts for age, gender and 
height.  BMI percentile is acquired by plotting the BMI number on the Center for Disease 
Control BMI-for-age growth charts (by gender) to obtain a percentile ranking.   
This indicator variable was created by classifying baseline BMI percentile as ‘less than 
the 25th percentile’, ‘between the 25th and the 85th percentile’ and ‘greater than the 85th 
percentile’.  The BMI class variable took on values ‘0’, ‘1’ and ‘2’ respectively.  The same was 
done for BMI percentile at 3 months.  
2.7.3 Antibodies 
GAD65 antibody values that were greater than 0.069 were deemed as ‘positive’ and IA2 
antibody values greater than 0.032 were deemed as ‘positive’.   
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2.8 STATISTICAL METHODS 
We summarized continuous data using basic descriptive statistics, such as the mean, 
standard deviation, minimum and maximum. Categorical data was analyzed using frequency 
counts. Two models were investigated; the first modeled the change in BMI percentile from 
onset to three months as the outcome, and the second modeled BMI percentile at 3 months as the 
outcome. Both models had the following baseline predictors: Gender, Age at onset, HLA-DQ 
type, C-peptide, HbA1c, Race and BMI percentile at onset. 
Multiple linear regression was used to analyze the relationship between BMI and 
predictors at baseline.  The data was analyzed using Statistical Analysis System (SAS) software 
using a Windows operating system. PROC GLM was used to fit the various regression models. 
This procedure allows for the automatic creation of indicator variables with the CLASS 
statement.  We also used PROC GPLOT to analyze the residuals for variance homogeneity. The 
Kolmogorov-Smirnov test as well as the quantile-quantile (QQPLOT) plot of the residuals in 
PROC UNIVARIATE was used to assess normality. 
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3.0  RESULTS 
3.1.1 Demographics 
Table 1 shows the distribution of race and gender.  Of the 19 black subjects, 32% are 
female.  The number of Caucasian subjects (94%) greatly outnumbered the number of black 
subjects (6%), although the ratio of male to female is comparable.   
 
Table 1. Cross tabulation depicting the 
relationship between gender and race among study 
participants. 
  RACE   
  White Black Total  
 GENDER     
 Male  
163 
55% 
13 
68% 
176 
56%  
 Female 
133 
45% 
6 
32% 
139 
44%  
 Total 
296 
94% 
19 
6% 
315 
100%  
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 3.1.2 Distribution Continuous Predictors 
Table 2 and Table 3 illustrate the distribution of the continuous predictors of interest. Of the 
predictors that we have at onset and at 3 months, all showed an average increase except HbA1c, 
which went from an average of 11.7% at onset to 7.36% at 3 months for an average change of -
4.35%.  
 
Table 2.  Descriptive statistics for baseline variables used in the 
study of Type I diabetes in children. 
Variable N Mean 
Std 
Dev Minimum Maximum 
Percentile for body 
mass index-for-age 
303 52.2 34.27 0.02 100 
Age at baseline in 
Years 
315 9.37 4.24 0.58 18.92 
C peptide: baseline 
(CHP) (ng/ml) 
287 0.88 0.82 0.5 7.01 
HbA1c (%) 306 11.7 2.4 5.3 17 
Triglyceride (mg/dl) 265 113 78 28 718 
HDL (mg/dl) 164 39 11 13 82 
LDL (mg/dl) 161 91 36 10 280 
Cholesterol (mg/dl) 268 148 36 51 319 
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Table 3.  Descriptive statistics for variables at time 3-months used in the study of 
Type I diabetes in children. 
Variable N Mean 
Std 
Dev Minimum Maximum
Percentile for body mass index-for-age 
(3 months) 
295 73.5 22.85 1.38 100 
Age at 3 months in Years 315 9.62 4.24 0.83 19.17 
C peptide (CHP) (ng/ml) 226 1.85 1.81 0.01 17.3 
HbA1c (%) 306 7.36 0.92 4.5 11.8 
Diastolic BP: 3 months 270 63.97 6.99 44 89 
Systolic BP: 3 months 271 110.19 12.75 81 180 
Average BP 270 87.06 8.59 69 125 
HDL 222 48 11 20.8 78.5 
Triglyceride 225 124 67 38 640 
cholesterol 225 154 28 80 293 
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Table 4.  Descriptive Statistics for Average Three Month Change. 
Label N Mean Std Dev Minimum Maximum 
Difference in BMI 295 21.52 24.58 -41.89 88.53 
Difference in age 315 0.25 0 0.25 0.25 
Difference in C-peptide 
(ng/ml) 213 1.04 1.6 -1.98 13.94 
Difference in HbA1C (%) 299 -4.35 2.52 -10.9 4.2 
Difference in HDL 117 9.42 10.7 -21.2 31.9 
Difference in Triglyceride 188 14.68 81.84 -423 259 
Difference in Cholesterol 190 8.17 30.25 -96 107 
      
 
 
 
 
 
 
3.1.3 Distribution Categorical Predictors 
We found no evidence of an effect of genes on BMI percentile, an explanation may be 
due to the under-representation of ASP and Non-ASP/0602, these genes only accounted for 3.6% 
and 1.8% of the total gene frequency respectively.   
Waist circumference was found to be significantly associated with BMI. Putting aside the 
‘75th and 85th percentile’ categories, the frequency of subjects were more or less evenly 
distributed. As mentioned earlier, we obtained an additional category (85th) from Dr. Fernandez; 
if we were to consolidate these two categories, the frequency of the waist circumference is 
interestingly almost evenly distributed.  Of the two hundred and one subjects who had a waist 
measurement, sixty-six percent were under the 75th percentile. The majority of subjects (43%) 
fell between the 25th and the 85th percentile in BMI. Table 5 shows their distributions and Figure 
1 through Figure 3 give a pictorial representation. 
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 Table 5.  Frequency distribution of HLA/DQ, 
waist percentiles, waist class and BMI class. 
Variable  Frequency   
HLA (n = 276)    
  ASP  
10 
3.6% 
 
  Non-ASP  
266 
95% 
 
  Non-ASP/0602  
5 
1.8% 
 
Waist Percentiles (n=201)    
  0th  
22 
11%  
  10th  
30 
15%  
  25th  
36 
18%  
  50th  
44 
22%  
  75th  
20 
10%  
  85th  
10 
5%  
  90th  
39 
19%  
    
Waist  Class (n =201)   
  < 75th  
132 
66%  
  >= 75th  
69 
34%  
BMI class (n = 315)    
  < 25th  
102 
32%  
  25th -  85th  
135 
43%  
  > 85th  
78 
25%  
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Figure 3: Percent Distribution of BMI Class 
3.1.4 Interpretation of the Regression Models 
BMI percentile at diagnosis was significantly different from BMI percentile at 3months, a 
paired t-test showed an average increase from baseline of 21.52 and a standard deviation of 
24.58 (p-value<0.0001).  Even though Caucasian subjects (n=276) vastly outnumbered the 
African American subjects (n=19), both races showed a significant increase in BMI percentile at 
3 months (with mean, standard deviation and p-value of [21.753, 24.14, p<0.0001]; [18.1, 30.9, 
p=0.02]). Table 6 and 7 show the regression outputs. 
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 Table 6.  Regression coefficients for BMI 
change as outcome. 
Parameter Estimate P-value 
Age at onset -0.67 0.0195 
C-peptide -1.22 0.4379 
A1C 1.83 0.0001 
Race  0.7744 
    Black -1.13  
    White *  
Gender  0.0011 
    Female -6.83  
    Male *  
HLA   
    ASP -3.24 0.7247 
    Non-Asp 2.13 0.7824 
    Non-Asp/0602 *  
BMI at Onset   
    25th to 85th percentile -25.27 <.0001 
    Over the 85th      
percentile 
-41.69 <.0001 
    Under the 25th 
percentile 
*  
      
* : Reflects the reference group 
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 Table 7.  Regression coefficients for BMI at 3-months as 
outcome. 
Parameter Estimate P-value   
Age at onset -0.58 0.0451  
C-peptide 0.02 0.9883  
A1C 1.95 <.0001  
Race  0.3017  
    Black 4.14   
    White *   
Gender  0.0048  
    Female -6.00   
    Male *   
HLA    
    ASP -5.01 0.5939  
    Non-Asp 1.81 0.8185  
    Non-Asp/0602 *   
BMI at Onset    
    25th to 85th percentile 19.18  <.0001  
    Over the 85th 
percentile 
42.36 <.0001 
 
    Under the 25th 
percentile 
*  
 
        
*: Reflects the reference group 
 
Greater change in BMI percentile from onset to 3 months was significantly associated 
with younger age, higher HbA1c, male gender and being under the 25th percentile in BMI at 
onset.  The subjects with the highest BMI percentile at 3 months were significantly associated 
with the independent predictors of younger age, higher HbA1c, male gender and being in the 85th 
percentile in BMI at onset. 
 One of the current theories is that individuals with the lowest risk HLA haplotypes (ASP) 
should have the lowest frequency of antibodies and highest BMI.  Table 8 shows the frequency 
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of positive antibodies versus HLA, and even with a high amount of missing data of these 
predictors, the results shows some sign of concurrence with this theory.  They are 4 individuals 
in this cross-tabulation of which 3 have the lowest risk haplotype.  Table 9 depicts the cross-
tabulation of HLA versus BMI percentile, here also, our data shows some accordance with the 
theoretical belief.  There are 4 individuals with the lowest risk haplotypes, and none of the 4 are 
under the 25th percentile at onset. 
Table 8.  Cross tabulation depicting the relationship between positive antibodies 
and HLA. 
HLA   
 ASP Non-ASP Non-ASP/0602 Total 
Positive Antibodies     
0 3 32 1 36 
1 1 40 1 42 
2 0 35 3 35 
Total 4 107 2 113 
          
     
 
Table 9.  Cross tabulation depicting the relationship between HLA and BMI. 
BMI         
 
Under 25th 
percentile 
25th - 85th 
percentile 
Over 85th 
percentile Total 
HLA     
ASP 0  
2 
 
2 
 4 
Non-ASP 32  
47 
 
28 
 107 
Non-ASP/0602 1  
1 
 
0 
 2 
Total 33 50 30 113 
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4.0  DISCUSSION 
We started the analysis with a larger range of predictors; these predictors were lipids, 
systolic and diastolic blood pressure, C-peptide, age, race, HLA-DQ, gender, waist 
circumference, antibodies and HbA1c. Lipids and blood pressures showed no evidence of an 
association with BMI percentile; this is true in the univariate and in the multivariate models. As 
stated earlier, no evidence was found of an association between antibodies and BMI; however an 
explanation might be the fact that we had only 120 subjects (38%) who had an antibody 
measurement. Waist circumference was quite interesting, in the fact that we found an association 
with BMI percentile. The addition of waist circumference did not change the effects of other 
predictors in the model as described in section (3.1.3), the subjects that are at least in the 75th 
percentile had the greatest change in BMI and the highest BMI percentile at 3 months. However, 
due to sparse waist circumference data, only 53% had a value for waist, the waist predictor was 
not included in the final model. Similarly, there was no association with the HLA haplotype 
(only 10 had ASP haplotypes) with BMI.  
Although age at onset is positively correlated with BMI at 3 months, after adjusting for 
BMI at onset or C-peptide along with the other covariates in the model, the effect of age is 
negative. Hence younger subjects are associated with a higher BMI at 3 months. This was 
verified by fitting all of the models on the subgroup with non-missing data for all the predictors. 
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5.0  CONCLUSION 
No definitive statement could be made about the relationship of positive antibodies and 
BMI.  Our data set only had two of the four antibodies that are suspected to be related to 
diabetes, and of the two antibodies, we had 120 out of 315 (38%) subjects who had antibody 
analysis. One of the current beliefs is that individuals with the lower risk HLA haplotypes (ASP) 
should have the lowest frequency of antibodies and highest BMI. However inconclusive; our 
data is consistent with this belief. 
  We have seen that a younger age, male gender, higher HbA1c is associated with the 
highest BMI percentile at 3 months and also with the highest degree of change in BMI percentile 
from onset to 3 months.  Future research should provide a more definitive statement about the 
relationship of antibodies, BMI and diabetes. 
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APPENDIX: TABLES 
 
Table 1A. Regression Coefficients from study of blood pressure. 
 
Variable   Regression 
Equation 
Symbol 
 Systolic 
BP 
   Diastolic 
BP 
  
       Male Female  Male Female 
Intercept  α  102.20 102.01  61.01 60.51 
Age         
Age-10   β1  1.82 1.94  0.68 1.01 
(Age-10)2   β2  0.13 0.01  -0.10 0.01 
(Age-10)3   β3  0.00 -0.01  0.02 0.00 
(Age-10)4   β4  0.00 0.00  0.00 0.00 
Normalized Height         
Zht  γ1  2.73 2.04  1.47 1.17 
Zht2  γ2  -0.20 0.03  -0.08 0.13 
Zht3  γ3  -0.05 -0.02  -0.03 -0.04 
Zht4  γ4  0.01 0.00  0.01 0.00 
Standard Deviation  σ  10.71 10.49  11.60 10.96 
ρ*    0.41 0.38  0.24 0.26 
n(persons)    32161.00 31066.00  24057.00 23443.00
n(visits)    42074.00 41017.00  29182.00 28794.00
                
 
 
 
 
 29 
  
 
 
 
 
Table 1B. Waist Percentiles for European American Boys 
  10th   25th  50th  75th  85th 90th   
Intercept 39.3 43.18 42.94 43.3 43.3727 43.83 
Slope 1.8 1.86 2.08 2.63 3.1091 3.39 
       
Age 10th   25th  50th  75th  85th 90th   
2 42.9 46.9 47.1 48.56 49.5909 50.61 
3 44.7 48.76 49.18 51.19 52.7 54 
4 46.5 50.62 51.26 53.82 55.8091 57.39 
5 48.3 52.48 53.34 56.45 58.9182 60.78 
6 50.1 54.34 55.42 59.08 62.0273 64.17 
7 51.9 56.2 57.5 61.71 65.1364 67.56 
8 53.7 58.06 59.58 64.34 68.2455 70.95 
9 55.5 59.92 61.66 66.97 71.3546 74.34 
10 57.3 61.78 63.74 69.6 74.4637 77.73 
11 59.1 63.64 65.82 72.23 77.5728 81.12 
12 60.9 65.5 67.9 74.86 80.6819 84.51 
13 62.7 67.36 69.98 77.49 83.791 87.9 
14 64.5 69.22 72.06 80.12 86.9001 91.29 
15 66.3 71.08 74.14 82.75 90.0092 94.68 
16 68.1 72.94 76.22 85.38 93.1183 98.07 
17 69.9 74.8 78.3 88.01 96.2274 101.46 
18 71.7 76.66 80.38 90.64 99.3365 104.85 
              
 
 
 
 
 30 
  
 
 
 
 
Table 1C.  Waist Percentiles European American Girls 
  10th   25th  50th  75th  85th 90th   
Intercept 39.88 41.76 43.64 45 45.4201 46.75 
Slope 1.6 1.68 1.89 2.3 2.69 2.87 
       
Age 10th   25th  50th  75th  85th 90th   
2 43.08 45.12 47.42 49.6 50.8001 52.49 
3 44.68 46.8 49.31 51.9 53.4901 55.36 
4 46.28 48.48 51.2 54.2 56.1801 58.23 
5 47.88 50.16 53.09 56.5 58.8701 61.1 
6 49.48 51.84 54.98 58.8 61.5601 63.97 
7 51.08 53.52 56.87 61.1 64.2501 66.84 
8 52.68 55.2 58.76 63.4 66.9401 69.71 
9 54.28 56.88 60.65 65.7 69.6301 72.58 
10 55.88 58.56 62.54 68 72.3201 75.45 
11 57.48 60.24 64.43 70.3 75.0101 78.32 
12 59.08 61.92 66.32 72.6 77.7001 81.19 
13 60.68 63.6 68.21 74.9 80.3901 84.06 
14 62.28 65.28 70.1 77.2 83.0801 86.93 
15 63.88 66.96 71.99 79.5 85.7701 89.8 
16 65.48 68.64 73.88 81.8 88.4601 92.67 
17 67.08 70.32 75.77 84.1 91.1501 95.54 
18 68.68 72 77.66 86.4 93.8401 98.41 
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Table 1D.  Waist Percentiles African American Boys 
  10th   25th  50th  75th  85th 90th   
Intercept 40.1 41.23 42.69 44.1 44.4782 43.58 
Slope 1.55 1.69 1.86 2.2 2.5719 3.21 
       
Age 10th   25th  50th  75th  85th 90th   
2 43.2 44.61 46.41 48.5 49.622 50 
3 44.75 46.3 48.27 50.7 52.1939 53.21 
4 46.3 47.99 50.13 52.9 54.7658 56.42 
5 47.85 49.68 51.99 55.1 57.3377 59.63 
6 49.4 51.37 53.85 57.3 59.9096 62.84 
7 50.95 53.06 55.71 59.5 62.4815 66.05 
8 52.5 54.75 57.57 61.7 65.0534 69.26 
9 54.05 56.44 59.43 63.9 67.6253 72.47 
10 55.6 58.13 61.29 66.1 70.1972 75.68 
11 57.15 59.82 63.15 68.3 72.7691 78.89 
12 58.7 61.51 65.01 70.5 75.341 82.1 
13 60.25 63.2 66.87 72.7 77.9129 85.31 
14 61.8 64.89 68.73 74.9 80.4848 88.52 
15 63.35 66.58 70.59 77.1 83.0567 91.73 
16 64.9 68.27 72.45 79.3 85.6286 94.94 
17 66.45 69.96 74.31 81.5 88.2005 98.15 
18 68 71.65 76.17 83.7 90.7724 101.36 
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Table 1E.  Waist Percentiles African American Girls 
  10th   25th  50th  75th  85th 90th   
Intercept 39.87 41.18 41.69 42.1 42.54 42.75 
Slope 1.56 1.71 2.13 2.82 3.33 3.675 
       
Age 10th   25th  50th  75th  85th 90th   
2 42.99 44.6 45.95 47.74 49.2 50.1 
3 44.55 46.31 48.08 50.56 52.53 53.775 
4 46.11 48.02 50.21 53.38 55.86 57.45 
5 47.67 49.73 52.34 56.2 59.19 61.125 
6 49.23 51.44 54.47 59.02 62.52 64.8 
7 50.79 53.15 56.6 61.84 65.85 68.475 
8 52.35 54.86 58.73 64.66 69.18 72.15 
9 53.91 56.57 60.86 67.48 72.51 75.825 
10 55.47 58.28 62.99 70.3 75.84 79.5 
11 57.03 59.99 65.12 73.12 79.17 83.175 
12 58.59 61.7 67.25 75.94 82.5 86.85 
13 60.15 63.41 69.38 78.76 85.83 90.525 
14 61.71 65.12 71.51 81.58 89.16 94.2 
15 63.27 66.83 73.64 84.4 92.49 97.875 
16 64.83 68.54 75.77 87.22 95.82 101.55 
17 66.39 70.25 77.9 90.04 99.15 105.225 
18 67.95 71.96 80.03 92.86 102.48 108.9 
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